Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alexander Nowak maintains a Buy rating on DiaMedica Therapeutics (NASDAQ:DMAC) but lowers the price target from $11 to $8.
March 21, 2024 | 6:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
DiaMedica Therapeutics' price target was lowered from $11 to $8 by Craig-Hallum, although the Buy rating was maintained.
The reduction in price target could have a mixed impact on DMAC's stock price. On one hand, the lowered target suggests a tempered expectation for the stock's future performance. On the other hand, maintaining a Buy rating indicates a continued positive outlook on the company by the analyst. The net effect on the stock price in the short term is uncertain, hence a neutral score is assigned.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100